Long-Term Ranibizumab Treatment in Neovascular Age-Related Macular Degeneration: A Belgian Subanalysis from the Global Real-World LUMINOUS^TM Study

Figures & data

Table 1 Patient Demographic and Clinical Characteristics at Study Entry, Study Discontinuation (N=229)

Parameters	Value
Age: median, mean±SD (n)	80.0, 79.5±7.7 (223)
Gender: Male: n (%)	74 (32.3)
Comorbidities^a: n (%)
Hypertension	119 (52.0)
Hyper-cholesterolemia/-lipidemia	107 (46.7)
History of coronary artery disease	28 (12.2)
Diabetes	19 (8.3)
Obesity	18 (7.9)
Myocardial infarction	14 (6.1)
Stroke	13 (5.7)
Other thromboembolic event	15 (6.6)
Secondary eyes treated: n (%)	53 (23.1)
Ocular history^a: n (%)
Pigment epithelium detachment	86 (37.6)
Lesion type: Predominantly classic	46 (20.1)
Lesion size (> 1 DA)	151 (65.9)
Choroidal neovascularization	216 (94.3)
Retinal angiomatous proliferation	20 (8.7)
Prior treatments: n (%)
None (treatment-naïve)	40 (17.5)
Prior treatment (including ranibizumab)	189 (82.5)
Other prior treatments (not including ranibizumab)	0 (0.0)
Time (months) since diagnosis: median, mean±SD (n)
All patients	15.0, 28.3±37.1 (229)
Treatment-naïve eyes	0.0, 6.9±22.4 (40)
Prior ranibizumab	21.0, 32.8±38.0 (189)
Ophthalmological parameters: median, mean±SD (n)
Visual acuity (ETDRS letters)
All patients	65.0, 62.9±14.0 (223)
Treatment-naïve	60.0, 59.6±15.8 (37)
Prior ranibizumab	65.0, 63.5±13.6 (186)
Central retinal thickness (µm)
All patients	275.0, 290.3±92.0 (223)
Treatment-naïve	324.0, 341.2±92.0 (38)
Prior ranibizumab	266.0, 279.8±88.7 (185)
Study discontinuation: n (%)	114 (49.8)
Lost to follow-up	43 (37.7)^b
Switch to other anti-VEGF agent	28 (24.6)^b
Death	18 (15.8)^b
Subject withdrawal	8 (7.0)^b
Unsatisfactory therapeutic event	5 (4.4)^b
Protocol deviation	4 (3.5)^b
Adverse event	4 (3.5)^b
Study drug no longer needed	2 (1.8)^b
Administrative problems	2 (1.8)^b

Notes: ^aCategories not mutually exclusive; ^b% of patients who discontinued the study (n=114).

Abbreviations: DA, disc area; ETDRS, Early Treatment Diabetic Retinopathy Study; SD, standard deviation; VEGF, vascular endothelial growth factor; µm, micrometer.

Table 2 Number of Visits and Number of Ranibizumab Injections (N=229)

		Number of Visits	Number of Injections
All patients	n^a	Median, mean±SD	Median, mean±SD
Yearly visits/injections (all years)	455	7.0, 7.6±2.9	4.0, 3.7±2.7
Year 1	184	8.0, 7.9±2.6	4.0, 4.4±2.7
Year 2	133	7.0, 7.1±2.4	3.0, 3.5±2.7
Year 3	97	7.0, 7.4±3.1	3.0, 2.8±2.4
Year 4	41	8.0, 8.7±4.1	4.0, 3.2±2.8
Treatment-naïve	n^a	Median, mean±SD	Median, mean±SD
Yearly visits/injections (all years)	75	8.0, 7.9±2.8	4.0, 4.2±2.9
Year 1	35	8.0, 8.4±3.1	5.0, 5.3±3.0
Year 2	21	7.0, 7.3±2.1	3.0, 3.8±2.5
Year 3	14	7.5, 8.0±3.0	2.5, 2.8±2.2
Year 4	5	7.0, 7.4±3.0	1.0, 2.4±2.5
Prior ranibizumab	n^a	Median, mean±SD	Median, mean±SD
Yearly visits/injections (all years)	380	7.0, 7.5±2.9	4.0, 3.6±2.7
Year 1	149	7.0, 7.7±2.5	4.0, 4.2±2.6
Year 2	112	7.0, 7.1±2.5	3.0, 3.4±2.8
Year 3	83	7.0, 7.3±3.1	3.0, 2.8±2.5
Year 4	36	8.0, 8.8±4.2	4.0, 3.3±2.8

Notes: ^an=number of visits/treatments for eyes up to their last completed year.

Abbreviation: SD, standard deviation.

Figure 1 Mean VA change (in ETDRS letters ± standard errors) from baseline per quarter.

Notes: Pre-treatment status category of the eye: Treatment-naïve=

; Prior ranibizumab =

. Baseline n (month 0)=number of patients; all other n=number of measurements within the quarter (multiple assessments per patient possible).

Abbreviations: ETDRS, Early Treatment Diabetic Retinopathy Study; VA, visual acuity.

Figure 2 Mean CRT change (in µm ± standard errors) from baseline per quarter.

Notes: Pre-treatment status category of the eye: Treatment-naïve=

; Prior ranibizumab =

. Baseline n (month 0)=number of patients; all other n=number of measurements within the quarter (multiple assessments per patient possible).

Abbreviations: CRT, central retinal thickness; µm, micrometer.